Association of insulin-related serum factors with colorectal polyp number and type in adult males

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 9, 2014, Pages 1843-1851

  Comstock, Sarah S ^a   Xu, Diana ^a   Hortos, Kari ^b   Kovan, Bruce ^b,c   McCaskey, Sarah ^b   Pathak, Dorothy R ^d   Fenton, Jenifer I ^a,b  

^a Michigan State University   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c Charter Township of Clinton   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BINDING PROTEIN; C PEPTIDE; INSULIN RELATED SERUM FACTOR; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; VASCULOTROPIN; ADVANCED GLYCATION END PRODUCT; INSULIN; INSULIN-RELATED FACTOR; SOMATOMEDIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; COLON ADENOMA; COLONOSCOPY; COLORECTAL POLYP; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; ADENOMA; BLOOD; COLON POLYP; COLORECTAL TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; STATISTICAL MODEL;

ADENOMA; AGED; C-PEPTIDE; COLONIC POLYPS; COLONOSCOPY; COLORECTAL NEOPLASMS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN; LOGISTIC MODELS; MALE; MIDDLE AGED; SOMATOMEDINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84907184732     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0249-T     Document Type: Article

References (50)

1. Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y, et al. Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS ONE 2013; 8: e53916.
2. Omata F, Deshpande GA, Ohde S, Mine T, Fukui T. The association between obesity and colorectal adenoma: systematic review and meta-analysis. Scand J Gastroenterol 2013; 48: 136-46.
3. Hursting SD, Digiovanni J, Dannenberg AJ, Azrad M, Leroith D, Demark-Wahnefried W, et al. Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev Res 2012; 5: 1260-72.
4. Moy KA, Jiao L, Freedman ND, Weinstein SJ, Sinha R, Virtamo J, et al. Soluble receptor for advanced glycation end products and risk of liver cancer. Hepatology 2013; 57: 2338-45.
5. Meyerhardt JA, Sato K, Niedzwiecki D, Ye C, Saltz LB, Mayer RJ, et al. Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Natl Cancer Inst 2012; 104: 1702-11.
6. Becker S, Dossus L, Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem 2009; 115: 86-96.
7. Hagberg CE, MehlemA, Falkevall A, Muhl L, Fam BC, Ortsater H, et al. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature 2012; 490: 426-30.
8. Brix JM, Hollerl F, Kopp HP, Schernthaner GH, Schernthaner G. The soluble form of the receptor of advanced glycation endproducts increases after bariatric surgery in morbid obesity. Int J Obes 2012; 36: 1412-7.
9. Lashinger LM, Ford NA, Hursting SD. Interacting inflammatory and growth factor signals underlie the obesity-cancer link. J Nutr 2014; 144: 109-13.
10. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012; 12: 159-69.
11. Comstock SS, Hortos K, Kovan B, McCaskey S, Pathak DR, Fenton JI. Adipokines and Obesity Are Associated withColorectal Polyps in Adult Males: A Cross-Sectional Study. PLoS ONE 2014; 9: e85939.
12. Yuan Y. Multiple Imputation Using SAS Software. J Stat Softw 2011; 45: 1-25.
13. Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, et al. Colonoscopic polypectomy and longterm prevention of colorectal-cancer deaths. N Engl J Med 2012; 366: 687-96.
14. Sridhar SS, Goodwin PJ. Insulin-insulin-like growth factor axis and colon cancer. J Clin Oncol 2009; 27: 165-7.
15. Palmqvist R, Hallmans G, Rinaldi S, Biessy C, Stenling R, Riboli E, et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut 2002; 50: 642-6.
16. Schoen RE, Weissfeld JL, Kuller LH, Thaete FL, Evans RW, Hayes RB, et al. Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. Gastroenterology 2005; 129: 464-75.
17. Neuhouser ML, Platz EA, Till C, Tangen CM, Goodman PJ, Kristal A, et al. Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Prev Res 2013; 6: 91-9.
18. Evdokimova V, Tognon CE, Benatar T, Yang W, Krutikov K, Pollak M, et al. IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. Sci Signal 2012; 5: ra92.
19. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-28.
20. Erarslan E, Coskun Y, Turkay C, Koktener A, Aydogan T. IGF-I levels and visceral fat accumulation in colonic neoplasia. Clin Res Hepatol Gastroenterol 2014; 38: 99-105.
21. Faupel-Badger JM, Berrigan D, Ballard-Barbash R, Potischman N. Anthropometric correlates of insulin-like growth factor 1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels by race/ethnicity and gender. Ann Epidemiol 2009; 19: 841-9.
22. Zhao C, Ivanov I, Dougherty ER, Hartman TJ, Lanza E, Bobe G, et al. Noninvasive detection of candidate molecular biomarkers in subjects with a history of insulin resistance and colorectal adenomas. Cancer Prev Res 2009; 2: 590-7.
23. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, et al. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2005; 14: 850-5.
24. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGFbinding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000; 92: 1592-600.
25. Anisimov VN, Bartke A. The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer. Crit Rev Oncol Hematol 2013; 87: 201-23.
26. Montrose DC, Zhou XK, Kopelovich L, Yantiss RK, Karoly ED, Subbaramaiah K, et al. Metabolic profiling, a noninvasive approach for the detection of experimental colorectal neoplasia. Cancer Prev Res 2012; 5: 1358-67.
27. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 2013; 30: 803-17.
28. Zhang X, Giovannucci EL, Wu K, Smith-Warner SA, Fuchs CS, Pollak M, et al. Magnesium intake, plasma C-peptide, and colorectal cancer incidence in US women: a 28-year follow-up study. Br J Cancer 2012; 106: 1335-41.
29. Patel N, Taveira TH, Choudhary G, Whitlatch H, WuWC. Fasting serum C-Peptide levels predict cardiovascular and overall death in nondiabetic adults. J Am Heart Assoc 2012; 1: e003152.
30. Vasic D, Walcher D. C-peptide: a new mediator of atherosclerosis in diabetes. Mediators Inflamm 2012; 2012: 858692.
31. Vidal AC, Lund PK, Hoyo C, Galanko J, Burcal L, Holston R, et al. Elevated C-peptide and insulin predict increased risk of colorectal adenomas in normal mucosa. BMC Cancer 2012; 12: 389.
32. Jenab M, Riboli E, Cleveland RJ, Norat T, Rinaldi S, Nieters A, et al. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007; 121: 368-76.
33. Chen L, Li L, Wang Y, Li P, Luo L, Yang B, et al. Circulating C-peptide level is a predictive factor for colorectal neoplasia: evidence from the meta-analysis of prospective studies. Cancer Causes Control 2013; 24: 1837-47.
34. Zhang X, Smith-Warner SA, Chan AT, Wu K, Spiegelman D, Fuchs CS, et al. Aspirin use, body mass index, physical activity, plasma Cpeptide, and colon cancer risk in US health professionals. Am J Epidemiol 2011; 174: 459-67.
35. Wang S, Wei W, Zheng Y, Hou J, Dou Y, Zhang S, et al. The role of insulin C-Peptide in the coevolution analyses of the insulin signaling pathway: a hint for its functions. PLoS ONE 2012; 7: e52847.
36. Marszalek A, Szylberg L, Wisniewska E, Janiczek M. Impact of COX-2, IL-1beta, TNF-alpha, IL-4 and IL-10 on the process of carcinogenesisin the large bowel. Pol J Pathol 2012; 63: 221-7.
37. Bobe G, Murphy G, Rogers CJ, Hance KW, Albert PS, Laiyemo AO, et al. Serum Adiponectin, Leptin, C-Peptide, Homocysteine, and Colorectal Adenoma Recurrence in the Polyp Prevention Trial. Cancer Epidemiol Biomarkers Prev 2010; 19: 1441-52.
38. Fung TT, Hu FB, Schulze M, Pollak M, Wu T, Fuchs CS, et al. A dietary pattern that is associated with C-peptide and risk of colorectal cancer in women. Cancer Causes Control 2012; 23: 959-65.
39. Theodoratou E, Farrington SM, Tenesa A, McNeill G, Cetnarskyj R, Korakakis E, et al. Associations between dietary and lifestyle risk factors and colorectal cancer in the Scottish population. Eur J Cancer Prev 2014; 23: 8-17.
40. Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010; 110: 911-16 e12.
41. Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H. Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci U S A 2012; 109: 15888-93.
42. Lindsey JB, Cipollone F, Abdullah SM, McGuire DK. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diab Vasc Dis Res 2009; 6: 7-14.
43. Norata GD, Garlaschelli K, Grigore L, Tibolla G, Raselli S, Redaelli L, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr Metab Cardiovasc Dis 2009; 19: 129-34.
44. Choi KM, Han KA, Ahn HJ, Hwang SY, Hong HC, Choi HY, et al. Effects of exercise on sRAGE levels and cardiometabolic risk factors in patients with type 2 diabetes: a randomized controlled trial. J Clin Endocrinol Metab 2012; 97: 3751-8.
45. Sung JY, Chung W, Kim AJ, Kim HS, Ro H, Chang JH, et al. Calcitriol treatment increases serum levels of the soluble receptor of advanced glycation end products in hemodialysis patients with secondary hyperparathyroidism. Tohoku J Exp Med 2013; 230: 59-66.
46. Jiao L, Taylor PR, Weinstein SJ, Graubard BI, Virtamo J, Albanes D, et al. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 1430-8.
47. Jiao L, Chen L, Alsarraj A, Ramsey D, Duan Z, El-Serag HB. Plasma soluble receptor for advanced glycation end-products and risk of colorectal adenoma. Int J Mol Epidemiol Genet 2012; 3: 294-304.
48. Kwon KA, Kim SH, Oh SY, Lee S, Han JY, Kim KH, et al. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 2010; 10: 203.
49. Martins SF, Garcia EA, Luz MA, Pardal F, Rodrigues M, Filho AL. Clinicopathological correlation and prognostic significance of VEGFA, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. Cancer Genomics Proteomics 2013; 10: 55-67.
50. Saif MW. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer? Anticancer Res 2013; 33: 2377-80.